Life Sciences

FDA approves Takeda’s Iclusig for Philadelphia chromoso...

Twelve years after the FDA initially granted limited approval to Takeda’s Iclusi...

Novo Nordisk invests $560 million to increase Chinese m...

Novo Nordisk, a prominent player in the pharmaceutical industry, is commemoratin...

Hippocratic AI Secures $53M Funding from General Cataly...

Hippocratic AI emerged from stealth mode approximately a year ago, unveiling its...

Promising phase 3 results propel Bayer’s menopause drug...

Bayer’s recent announcement regarding its intention to seek regulatory approval ...

AstraZeneca Acquires Amolyt Pharma, Expanding into Rare...

AstraZeneca has made a strategic move into the realm of rare endocrinology with ...

AstraZeneca’s $2 Billion Acquisition of Fusion Pharmace...

AstraZeneca’s decision to integrate Fusion Pharmaceuticals into its cancer divis...

No Proof of Brain Injury in ‘Havana Syndrome’ Patients

A comprehensive series of sophisticated examinations conducted by researchers re...

Lexicon Pharmaceuticals on Track to Resubmit Sotagliflo...

Ever since facing its initial setback with the FDA half a decade ago, Lexicon Ph...

City of Hope & Mustang Bio’s CAR-T Therapy Shows Promis...

For patients with recurrent glioblastoma, the chimeric antigen receptor T-cell (...

Lexicon Set to Resubmit Zynquista for Type 1 Diabetes T...

Since its initial rejection by the FDA approximately five years ago, Lexicon Pha...

Pfizer’s Adcetris Shows Promise in Extending Survival f...

The pharmaceutical giant Pfizer revealed positive results from a late-stage stud...

HiLabs Completes $39 Million Funding Round as Company E...

HiLabs, a health technology enterprise powered by artificial intelligence, is de...

Eli Lilly’s Lebrikizumab Shows Promise in Eczema Treatm...

Eli Lilly’s recent breakthrough in eczema treatment represents a stride in addre...

Incyte Meets Midphase Skin Condition Trial Goal

In its pursuit of Regeneron and Sanofi’s Dupixent in the treatment of prurigo no...

FDA Lifts Partial Hold on Iovance’s Cancer Therapy Trial

Iovance Biotherapeutics has had a partial clinical hold imposed by the FDA. This...

Merck KgaA Offers $16M For Two C4 Degraders

Merck KGaA has been brought on board by the Massachusetts biotechnology company ...